Richard Stefanacci, DO, associate professor, Health Policy & Public Health, University of the Sciences, says that scanning and diagnostic testing are currently the most popular trend in neurodegenerative diseases.
Richard Stefanacci, DO, associate professor, Health Policy & Public Health, University of the Sciences, says that scanning and diagnostic testing are currently the most popular trend in neurodegenerative diseases.
There are new technologies being utilized, but it is important they are used on the right patients at the right time. "It requires the plans to educate providers to make sure they are identifiying the right patients in doing these tests," said Dr Stefanacci.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More